A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations
Sign Up to like & getrecommendations! Published in 2022 at "Acta Haematologica"
DOI: 10.1159/000525566
Abstract: Introduction: RAS pathway mutations are common mechanisms of resistance to acute myeloid leukemia (AML) therapies. Trametinib, an oral MEK inhibitor, has been shown to have single-agent activity in relapsed/refractory AML and preclinical synergy with venetoclax.… read more here.
Keywords: venetoclax trametinib; ras pathway; relapsed refractory; azacitidine venetoclax ... See more keywords
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003902
Abstract: The phase 3 VIALE-A trial reported that venetoclax in combination with azacitidine significantly improved response rates and overall survival compared with azacitidine alone in older, unfit patients with previously untreated acute myeloid leukemia (AML). However,… read more here.
Keywords: cost effectiveness; azacitidine; previously untreated; azacitidine venetoclax ... See more keywords